| 000 | 01834 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515000611.0 | ||
| 264 | 0 | _c20051114 | |
| 008 | 200511s 0 0 eng d | ||
| 022 | _a0090-0036 | ||
| 024 | 7 |
_a10.2105/AJPH.2004.056150 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFarley, John | |
| 245 | 0 | 0 |
_aFeasibility and outcome of HCV treatment in a Canadian federal prison population. _h[electronic resource] |
| 260 |
_bAmerican journal of public health _cOct 2005 |
||
| 300 |
_a1737-9 p. _bdigital |
||
| 500 | _aPublication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBritish Columbia _xepidemiology |
| 650 | 0 | 4 |
_aDNA, Viral _xgenetics |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFederal Government |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepacivirus _xclassification |
| 650 | 0 | 4 |
_aHepatitis C _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethadone _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 |
_aNarcotics _xtherapeutic use |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 |
_aPrisons _xorganization & administration |
| 650 | 0 | 4 | _aProgram Evaluation |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSubstance Abuse, Intravenous _xcomplications |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aVasdev, Shawn | |
| 700 | 1 | _aFischer, Benedikt | |
| 700 | 1 | _aHaydon, Emma | |
| 700 | 1 | _aRehm, Jürgen | |
| 700 | 1 | _aFarley, Theresa A | |
| 773 | 0 |
_tAmerican journal of public health _gvol. 95 _gno. 10 _gp. 1737-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2105/AJPH.2004.056150 _zAvailable from publisher's website |
| 999 |
_c15767877 _d15767877 |
||